Hair Growth After Cancer; ‘Global’ Early-Onset CRC; Retifanlimab Boosts OS in NSCLC

Oral minoxidil promoted hair regrowth with no serious side effects in women who had hair loss related to breast cancer treatment. (NYU Langone Health, Journal of the American Academy of Dermatology)

The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were found in some of the antidepressant tablets.

People who are prone to accelerated aging may benefit from early screening for colorectal cancer (CRC). (University of Miami Sylvester Comprehensive Cancer Center, Cancer Prevention Research)

Mixed results from adding immunotherapy to chemoradiation or radiotherapy for non-small cell lung cancer (NSCLC): Adding nivolumab (Opdivo) to concurrent chemoradiation followed by maintenance nivolumab failed to improve progression-free survival (PFS) and increased the risk of adverse events in patients with unresectable/metastatic disease. On the other hand, post-irradiation durvalumab (Imfinzi) appeared to improve PFS in older, frail patients with NSCLC. (European Society for Medical Oncology)

Bipartisan legislation introduced in the Senate would prohibit companies that control health insurers or pharmacy benefit managers from owning pharmacies. (STAT)

Authors of a new report from the American Cancer Society call the recent surge in early-onset CRC a “global phenomenon.”

LAVA Therapeutics announced discontinuation of an early-stage trial of its bispecific antibody targeting prostate-specific membrane antigen for lack of efficacy in metastatic castration-resistant prostate cancer.

Adding retifanlimab (Zynyz) to platinum-based chemotherapy improved overall survival in previously treated NSCLC, Incyte announced.

An investigational blood test showed potential for identifying patients with advanced prostate cancer that is unlikely to respond to ongoing treatment, perhaps allowing an earlier switch to different therapy. (University of Minnesota, Nature Communications)

Adding the PLK1 inhibitor onvansertib to standard of care doubled the response rate in first-line treatment of RAS-mutated CRC, Cardiff Oncology announced.

The FDA has tweaked its accelerated approval program to require that confirmatory trials must be underway at the time of approval, with limited exceptions, and to include more succinct labeling regarding potential limitations of a therapy’s usefulness and benefits.